Latest Subcutaneous emphysema Stories

Chronic exposure to tobacco smoke in childhood may contribute to early emphysema later in life, according to new research. Environmental tobacco smoke (ETS) is known to be associated with a variety of serious health problems, but it had not previously been associated with the development of emphysema over the life course. The data will be presented on Tuesday, May 19, at the 105th International Conference of the American Thoracic Society in San Diego."Emphysematous 'holes' in the lung...

Acquisition of Zephyr(R) EBV Technology Enables Pulmonx to Develop Both Assessment Tools and Therapeutic Solutions for Emphysema PALO ALTO, Calif., May 13 /PRNewswire/ -- Pulmonx, a medical device company focused on advancing therapies for patients with emphysema, announced today that it has acquired all of the assets of Emphasys Medical, including its endobronchial valve (EBV) technology platform and associated intellectual property. Pulmonx has now assumed global sales, marketing,...

The author of an upcoming biography about Michael Jackson says the fading U.S. pop star needs a lung transplant. Britain's The Sun newspaper quoted Canadian scribe Ian Halperin as saying the eccentric, 50-year-old Thriller singer suffers from the rare genetic disorder Alpha-1 anti-trypsin deficiency, which means he lacks a certain protein that protects his lungs. He needs a lung transplant, but may be too weak to go through with it. He also has emphysema and chronic gastrointestinal...

U.S. scientists are studying an investigational emphysema treatment that involves using stents to create new pathways for air in diseased lungs. Researchers at the National Jewish Medical and Research Center said the new procedure involves creating openings in the airway wall connecting the damaged lung tissue to the natural airway in a minimally invasive procedure. The holes, kept open by small stents, could relieve the hyperinflation of the lungs, allowing the healthy parts of the lungs to...

Spiration, Inc., a developer of novel medical devices designed to benefit patients with acute and chronic conditions of the lung, announced today that the company has received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA) for the use of its minimally invasive IBV(R) Valve System to control prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged, following lobectomy, segmentectomy, or lung volume reduction...

Patients in the Valley with emphysema might soon be breathing a little easier thanks to a new airway bypass study called the Exhale Airways Stents for Emphysema (EASE) trial. The trial principal is Dr. Karl Van Gundy aided by investigators Drs. Michael Peterson, Jose Joseph, Timothy Evans and Kathryn Bilello -- all pulmonologists at UCSF Fresno Medical Education Program. The study is a multi-center, international trial that is designed to evaluate the safety and effectiveness of this new and...

Switzerland-based Kuros Biosurgery has granted US-based Aeris Therapeutics an exclusive license in the field of lung volume reduction to certain patent rights Kuros exclusively licensed from the American Red Cross that cover the delivery of certain drugs in a fibrin sealant. In return for the license, Kuros will receive upfronts, milestones and royalties on the sale of Aeris's lead product, the AeriSeal biologic lung volume reduction (BLVR) system, a novel investigational emphysema...

Kuros Biosurgery AG and Aeris Therapeutics, Inc., both privately held biotech companies, announced today that Kuros has granted Aeris an exclusive license in the field of lung volume reduction to certain patent rights Kuros exclusively licensed from the American Red Cross that cover the delivery of certain drugs in a fibrin sealant. In return for the license, Kuros will receive upfronts, milestones and royalties on the sale of Aeris' lead product, the AeriSeal(TM) Biologic Lung Volume...

Aeris Therapeutics, Inc. (www.aerist.com), a company specializing in the development and commercialization of novel treatments for patients with emphysema and other advanced lung diseases, today announced that the primary efficacy endpoint in Phase 2 clinical trials for its Biologic Lung Volume Reduction (BLVR) System has been achieved. BLVR is designed to provide a safe non-surgical alternative to lung volume reduction surgery, one of the few available treatments for patients with advanced...

Spiration, Inc., a developer of novel medical devices designed to benefit patients with severe and chronic conditions of the lung, announced today that it has signed a definitive agreement giving Olympus Medical Systems Corp. exclusive development and distribution rights in Japan for the IBV(R) Valve System. The IBV Valve System is a minimally invasive treatment that has diverse applications in both acute and chronic conditions of the lung. In Europe, the system has received market...